Topiramate is also found in the weight-loss drug Qnexa that is manufactured by Vivus Incorporated. This drug has been rejected by the FDA last year because of the potential for birth defects as well as other reasons. The FDA is requiring further studies on birth defects from Vivus before this drug will be marketable.
Helping families affected by Topamax birth defects involving a cleft palate after taking this epilepsy drug during pregnancy and representing individuals who have developed heart, cranial and abdominal birth defects in filing Topamax lawsuits. 2011 cases are being filed individually and no nationwide Topamax class action lawsuithas been filed.
Topamax has become one of the most widely prescribed drugs for migraine headaches. Women are three times more likely to suffer from migraines than men, especially during the ages within which they would have children. Additionally, Topamax has an off-label use for obesity treatment.
After several studies regarding the alleged link between Topamax use and major birth injuries were released, the FDA increased the pregnancy category of Topamax from C to D, meaning the drug has the potential to cause significant, unreasonable harm to a human fetus.
Cleft palate Topamax birth defect is similar in nature to a cleft lip, but is characterized instead by a malformation of the infant’s palate. A cleft palate can occur on one or both sides of the mouth and can affect the soft back portion of the mouth or the body front portion of the mouth.
